Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued
Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...
来自MSN1 小时
Research Paves Way for Off-the-Shelf CAR T Cells for Cancer Treatment
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
Pharm Exec14 天
The Bottlenecks Blocking Cell and Gene Therapy
Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.
Pharmabiz1 天
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed ...
Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
India’s first global CAR T-cell therapy for Non-Hodgkin’s Lymphoma launched
India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects ...
Taiwan News8 天
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 ...